2-hydroxy-5-(4'-fluoro-2'-methylphenyl)benzoic acid | 64465-64-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-hydroxy-5-(4'-fluoro-2'-methylphenyl)benzoic acid
• 英文别名: 4a(2)-Fluoro-4-hydroxy-2a(2)-methyl[1,1a(2)-biphenyl]-3-carboxylic acid；5-(4-fluoro-2-methylphenyl)-2-hydroxybenzoic acid
• CAS: 64465-64-1
• 化学式: C₁₄H₁₁FO₃
• 分子量: 246.238
• InChiKey: UBDUVQFTPZZVKD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  二氧化碳 、 4-氟-2-甲基苯胺 、 苯 生成 2-hydroxy-5-(4'-fluoro-2'-methylphenyl)benzoic acid
  参考文献：
  名称：

  Novel analgesic-antiinflammatory salicylates

  摘要：

  5-(2,4-Difluorophenyl)salicylic acid, diflunisal (25), is the best compound, in terms of both efficacy and safety, from over 500 salicylates investigated in our laboratories. It is a chemically distinct, nonacetylating salicylic acid, more active than aspirin as an analgesic and antiinflammatory agent and superior in duration of action and therapeutic index. Some recent clinical and biochemical observations are briefly discussed.

  DOI：

  10.1021/jm00209a001

文献信息

• Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
  申请人：KemPharm, Inc.

  公开号：US10849981B2

  公开（公告）日：2020-12-01

  The presently described technology provides methods of treating a patient having moderate to severe pain, narcotic or opioid abuse or narcotic or opioid withdrawal. The presently described methods are carried out by comprising administering to the patient a pharmaceutically effective amount of a composition comprising acetaminophen and benzoate-hydrocodone hydrochloride. The composition has reduced side effects when compared with unconjugated hydrocodone.

  本技术提供了治疗中度至重度疼痛、滥用麻醉剂或阿片类药物或麻醉剂或阿片类药物戒断的患者的方法。所述方法包括向患者施用药学有效量的组合物，该组合物由对乙酰氨基酚和盐酸苯甲酸氢可酮组成。与未结合的氢可酮相比，该组合物的副作用较小。
• Methods and reagents for the treatment of metabolic disorders
  申请人：Lee S. Margaret

  公开号：US20060069161A1

  公开（公告）日：2006-03-30

  The invention features compositions, methods, and kits for the treatment of metabolic disorders such as diabetes and obesity.

  本发明的特点是用于治疗糖尿病和肥胖症等代谢性疾病的组合物、方法和试剂盒。
• TOPICAL USE OF HALOSALICYLIC ACID DERIVATIVES
  申请人：AVON PRODUCTS, INC.

  公开号：EP1694337A2

  公开（公告）日：2006-08-30
• EP1781303A4
  申请人：——

  公开号：EP1781303A4

  公开（公告）日：2008-07-02
• METHODS AND REAGENTS FOR THE TREATMENT OF METABOLIC DISORDERS
  申请人：CombinatoRx, Incorporated

  公开号：EP1781303A1

  公开（公告）日：2007-05-09